Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Miransertib × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Proteus Syndrome 1

Interventions

pembrolizumab 1115 Specimen Handling 744 Carboplatin 742 Cyclophosphamide 716 Magnetic Resonance Spectroscopy 695 Cisplatin 636 Nivolumab 610 Paclitaxel 559 Radiotherapy 498 Gemcitabine 491 Biopsy 456 Bevacizumab 413 Dexamethasone 396 fludarabine 349 Docetaxel 347 venetoclax 340 Oxaliplatin 326 Fluorouracil 325 atezolizumab 319 Capecitabine 318 Rituximab 312 durvalumab 296 Doxorubicin 281 Pemetrexed 279 Radiosurgery 273 Ipilimumab 271 Drug Therapy 270 Standard of Care 261 Lenalidomide 252 Radiation 252

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04316546 2026-03-11

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡